Anjali Cremer

Frankfurt Am Main, HE, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

IntegrateALL: An end-to-end RNA-seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B-precursor ALL.

IntegrateALL: An end-to-end RNA-seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B-precursor ALL.

Journal: HemaSphere
Published: September 30, 2025

USP22 is a novel vulnerability regulating MEIS1 protein abundance and gene transcription in KMT2Ar acute leukemia.

USP22 is a novel vulnerability regulating MEIS1 protein abundance and gene transcription in KMT2Ar acute leukemia.

Journal: Blood
Published: September 29, 2025

Inflammatory signaling pathways play a role in SYK inhibitor resistant AML.

Inflammatory signaling pathways play a role in SYK inhibitor resistant AML.

Journal: Scientific reports
Published: November 15, 2024

Central nervous system relapse after allogeneic HCT in FLT3-mutated AML.

Central nervous system relapse after allogeneic HCT in FLT3-mutated AML.

Journal: Annals of hematology
Published: August 21, 2024

Interventional antibiotic treatment replacing antibiotic prophylaxis during allogeneic hematopoietic stem cell transplantation is safe and leads to a reduction of antibiotic administration.

Interventional antibiotic treatment replacing antibiotic prophylaxis during allogeneic hematopoietic stem cell transplantation is safe and leads to a reduction of antibiotic administration.

Journal: Annals of hematology
Published: April 03, 2024

Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors.

Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: January 23, 2024

Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML.

Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML.

Journal: Annals of hematology
Published: April 12, 2023

Time's up: mutation rate and lifespan.

Time's up: mutation rate and lifespan.

Journal: Signal transduction and targeted therapy
Published: May 19, 2022

SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccination.

SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccination.

Journal: European journal of immunology
Published: December 15, 2021

The proteogenomic subtypes of acute myeloid leukemia.

The proteogenomic subtypes of acute myeloid leukemia.

Journal: Cancer cell
Published: April 21, 2021

IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia.

IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia.

Journal: Nature cancer
Published: April 15, 2021

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium.

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium.

Journal: Cancer discovery
Published: May 04, 2020
Showing 1-12 of 20

Last Updated: 09/26/2026